Please login to the form below

Not currently logged in
Email:
Password:

AZ licensing agreement with Aurobindo

Aurobindo Pharma has announced a licensing and supply agreement with AstraZeneca to supply certain generic products for emerging markets

Aurobindo Pharma has announced a licensing and supply agreement with AstraZeneca (AZ) to supply the Anglo-Swedish drugmaker with certain generic products to be sold in emerging markets.

The generics involved in the agreement include several solid dosage and sterile products and offer therapeutic care in such areas as anti-infectives, as well as covering conditions affecting the cardiovascular system (CVS) and the central nervous system (CNS).

Financial terms of the deal were not disclosed.

India-based Aurobindo manufactures generic pharmaceuticals and active pharmaceutical ingredients, with products marketed in over 125 countries.

This is Aurobindo's second deal with a major global pharmaceutical company to supply drugs for emerging markets following an agreement with Pfizer in 2009.

Speaking on the deal, Kaushik Banerjee, head of branded generics operations at AstraZeneca said "These agreements will enable us to extend the range of branded medicines we are able to offer patients in emerging markets, where we see continued opportunities to grow our business."

Aurobindo chairman P V Ramprasad Reddy said: “Aurobindo's proven track record in building strong, collaborative working relationships is a key driver for these strategic agreements with AstraZeneca which will accelerate our growth plans and support our earnings."

7th September 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...

Infographics